首页> 外文期刊>国际肝胆胰疾病杂志(英文版) >Necessity and indications of invasive treatment for Budd-Chiari syndrome
【24h】

Necessity and indications of invasive treatment for Budd-Chiari syndrome

机译:布加综合征综合治疗的必要性和适应症

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: The development of collaterals in Budd-Chiari syndrome has been described and these collaterals play an important role in the presentation of this disease. These collaterals are diagnostic and their use in management strategy has never been evaluated. This study aimed to investigate the indications, feasibility and necessity of invasive treatment for patients with Budd-Chiari syndrome and to determine whether such a strategy is necessary for optimal management. METHODS: Twenty-nine patients who had been treated at our unit were enrolled in this study. Based on physical and biochemical examination, and hemodynamic compensation by collaterals, 18 patients underwent radiological intervention (group A), while the other 11 had no invasive treatment (group B). The related hemodynamic parameters were acquired when percutaneous angiography was performed. RESULTS: In group A, all patients underwent successfully inferior vena cava (IVC) balloon angioplasty with or without stenting. Four patients also underwent hepatic vein angioplasty. In these patients, the mean IVC pressure before and after treatment was statistically different (29.3±9.2 vs 15.1±4.6 mmHg, P<0.01). The mean IVC pressure was much lower in group B than in group A (12.9±2.4 vs 29.3±9.2 mmHg, P<0.01), but there was no difference from that of the patients after radiological treatment (12.9±2.4 vs 15.1±4.6 mmHg, P>0.05). Median follow-up was 32.3 months (mean 21.3 months; range 3-61 months). In the course of follow-up, the patients in group A survived with good systemic status except for re-stenosis in one patient who underwent re-canalization of the IVC. In group B, 10 patients had good systemic status except one patient who had a meso-caval shunt because of deterioration. CONCLUSIONS: The rationale of "early diagnosis and early treatment" is not suitable for all patients with Budd-Chiari syndrome. Satisfactory survival can be achieved in some patients without invasive treatment, who are completely compensated by rich collaterals. Nonetheless, a positive treatment procedure should be performed if the patient's situation worsens in the course of regular follow-up.
机译:背景:已经描述了Budd-Chiari综合征中侧支的发展,这些侧支在这种疾病的表现中起着重要作用。这些抵押品是诊断性的,它们在管理策略中的用途从未得到过评估。这项研究旨在调查对布加综合征患者进行侵入性治疗的适应症,可行性和必要性,并确定这种策略对于最佳治疗是否必要。 方法:在我们单位接受治疗的29位患者参加了本研究。根据物理和生化检查以及附带的血液动力学补偿,有18例患者接受了放射学干预(A组),而其他11例没有进行侵入性治疗(B组)。经皮血管造影时获取相关的血液动力学参数。 结果:在A组中,所有患者均成功进行了有或没有支架的下腔静脉(IVC)球囊血管成形术。四名患者还接受了肝静脉血管成形术。在这些患者中,治疗前后的平均IVC压力有统计学差异(29.3±9.2 vs 15.1±4.6 mmHg,P <0.01)。 B组的平均IVC压力远低于A组(12.9±2.4 vs 29.3±9.2 mmHg,P <0.01),但与放射治疗后的患者无差异(12.9±2.4 vs 15.1±4.6) mmHg,P> 0.05)。中位随访时间为32.3个月(平均21.3个月;范围3-61个月)。在随访过程中,除1例行IVC再次根管治疗的患者再次狭窄外,A组患者均以良好的全身状态存活。在B组中,除了一名因恶化而进行中空分流的患者外,有10名患者的全身状态良好。 结论:““早期诊断和早期治疗”的基本原理并不适合所有Budd-Chiari综合征患者。在不进行侵入性治疗的情况下,某些患者可以得到令人满意的生存,而这些患者完全可以通过丰富的抵押品获得补偿。但是,如果在定期随访过程中患者的病情恶化,则应执行积极的治疗程序。

著录项

  • 来源
    《国际肝胆胰疾病杂志(英文版)》 |2011年第003期|254-260|共7页
  • 作者单位

    Department of General Surgery, Institute of Hepatic Vascular Disease, Department of Radiological Intervention, First Affiliated Hospital, Zhengzhou University School of Medicine, Zhengzhou 450052, China;

    Department of General Surgery, Institute of Hepatic Vascular Disease, Department of Radiological Intervention, First Affiliated Hospital, Zhengzhou University School of Medicine, Zhengzhou 450052, China;

    Department of General Surgery, Institute of Hepatic Vascular Disease, Department of Radiological Intervention, First Affiliated Hospital, Zhengzhou University School of Medicine, Zhengzhou 450052, China;

    Department of General Surgery, Institute of Hepatic Vascular Disease, Department of Radiological Intervention, First Affiliated Hospital, Zhengzhou University School of Medicine, Zhengzhou 450052, China;

    Department of General Surgery, Institute of Hepatic Vascular Disease, Department of Radiological Intervention, First Affiliated Hospital, Zhengzhou University School of Medicine, Zhengzhou 450052, China;

    Department of General Surgery, Institute of Hepatic Vascular Disease, Department of Radiological Intervention, First Affiliated Hospital, Zhengzhou University School of Medicine, Zhengzhou 450052, China;

    Department of General Surgery, Institute of Hepatic Vascular Disease, Department of Radiological Intervention, First Affiliated Hospital, Zhengzhou University School of Medicine, Zhengzhou 450052, China;

    Department of General Surgery, Institute of Hepatic Vascular Disease, Department of Radiological Intervention, First Affiliated Hospital, Zhengzhou University School of Medicine, Zhengzhou 450052, China;

    Department of General Surgery, Institute of Hepatic Vascular Disease, Department of Radiological Intervention, First Affiliated Hospital, Zhengzhou University School of Medicine, Zhengzhou 450052, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:39:19
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号